c-Maf nuclear oncoprotein is frequently expressed in multiple myeloma [7]

Leukemia

Volumn 21, Issue 7, 2007, Pages 1572-1574

  Chang, Hong ^a   Qi, Q ^a   Xu, W ^b   Patterson, B ^a  

^a TORONTO GENERAL HOSPITAL   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; IMMUNOGLOBULIN G; MELPHALAN; MESSENGER RNA; SYNDECAN 1; TRANSCRIPTION FACTOR C MAF;

ADULT; AGED; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW BIOPSY; CANCER RISK; CANCER SURVIVAL; CHROMOSOME TRANSLOCATION 14; CHROMOSOME TRANSLOCATION 16; CLINICAL FEATURE; CONTROLLED STUDY; CYTOGENETICS; DISEASE FREE SURVIVAL; DRUG MEGADOSE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENETIC RISK; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LETTER; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; OVERALL SURVIVAL; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL TIME;

EID: 34250767674     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404669     Document Type: Letter

References (8)

1. Nishizawa M, Kataoka K, Goto N, Fujiwara KT, Kawai S. v-maf, a viral oncogene that encodes a 'leucine zipper' motif. Proc Natl Acad Sci USA 1989; 86: 7711-7715.
2. Chesi M, Bergsagel PL, Shonukan OO, Martelli ML, Brents LA, Chen T et al. Frequent dysregulation of c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. Blood 1998; 91: 4457-4463.
3. Hurt EM, Wiestner A, Rosenwald A, Shaffer AL, Campo E, Grogan T et al. Over expression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell 2004; 5: 191-199.
4. Suzuki A, Iida S, Kato-Uranishi M, Tajima E, Zhan F, Hanamura I et al. ARK5 is transcriptionally regulated by the Large-MAF family and mediates IGF-1-induced cell invasion in multiple myeloma: ARK5 as a new molecular determinant of malignant multiple myeloma. Oncogene 2005; 24: 6936-6944.
5. Avet-Loiseau H, Facon T, Grobois B, Magrangeas F, Rapp MJ, Harousseau JL et al. Intergroupe Francophone du Myelome. Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood 2002; 99: 2185-2191.
6. Fonseca R, Blood E, Rue M, Harrington D, Oken MM, Kyle RA et al. Clinical biologic implications of recurrent genomic aberrations in myeloma. Blood 2003; 101: 4569-4575.
7. Chang H, Samiee S, Qi WY, Yi QL, Mikhael J, Chen C et al. Genetic risk identifies myeloma patients who do not benefit from autologous stem cell transplantation. Bone Marrow Transplant 2005; 36: 793-796.
8. Chang H, Stewart AK, Qi XY, Li ZH, Yi QL, Trudel S. Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myeloma. Blood 2005; 106: 353-355.